Evolus (NASDAQ:EOLS) Trading Up 7.9% - Should You Buy?

Evolus, Inc. (NASDAQ:EOLS - Get Free Report)'s stock price rose 7.9% during mid-day trading on Monday . The company traded as high as $9.85 and last traded at $9.92. Approximately 989,651 shares traded hands during trading, an increase of 38% from the average daily volume of 716,688 shares. The stock had previously closed at $9.19.

Wall Street Analyst Weigh In

EOLS has been the topic of several recent analyst reports. Needham & Company LLC reaffirmed a "buy" rating and set a $22.00 target price on shares of Evolus in a research note on Thursday, May 8th. Barclays lifted their target price on shares of Evolus from $22.00 to $25.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. BTIG Research started coverage on Evolus in a report on Thursday, April 17th. They issued a "buy" rating and a $21.00 target price on the stock. Finally, HC Wainwright reissued a "buy" rating and issued a $27.00 price target on shares of Evolus in a report on Thursday, April 10th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Evolus presently has a consensus rating of "Buy" and a consensus price target of $23.75.

Evolus Stock Down 1.6%

The stock's 50-day moving average price is $10.47 and its 200-day moving average price is $11.93. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The company has a market cap of $631.86 million, a P/E ratio of -10.77 and a beta of 1.11.

Insiders Place Their Bets

In other Evolus news, Director Karah Herdman Parschauer sold 12,888 shares of the company's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $12.99, for a total value of $167,415.12. Following the completion of the sale, the director now owns 32,183 shares in the company, valued at $418,057.17. This represents a 28.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider David Moatazedi sold 15,787 shares of the firm's stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $9.87, for a total value of $155,817.69. Following the transaction, the insider now owns 492,832 shares of the company's stock, valued at approximately $4,864,251.84. The trade was a 3.10% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 86,241 shares of company stock worth $1,048,666 in the last three months. 5.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Tang Capital Management LLC boosted its stake in Evolus by 3.1% in the 4th quarter. Tang Capital Management LLC now owns 4,997,399 shares of the company's stock worth $55,171,000 after purchasing an additional 150,000 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Evolus by 2.0% during the first quarter. Vanguard Group Inc. now owns 3,234,068 shares of the company's stock valued at $38,906,000 after purchasing an additional 62,664 shares in the last quarter. Nantahala Capital Management LLC increased its stake in Evolus by 10.8% during the 4th quarter. Nantahala Capital Management LLC now owns 3,130,149 shares of the company's stock worth $34,557,000 after buying an additional 305,300 shares in the last quarter. Caligan Partners LP boosted its position in Evolus by 22.7% during the fourth quarter. Caligan Partners LP now owns 2,692,388 shares of the company's stock worth $29,724,000 after acquiring an additional 498,900 shares during the last quarter. Finally, Millennium Management LLC grew its holdings in Evolus by 1.7% in the 1st quarter. Millennium Management LLC now owns 1,392,028 shares of the company's stock valued at $16,746,000 after buying an additional 23,605 shares in the last quarter. 90.69% of the stock is currently owned by hedge funds and other institutional investors.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.